[{"id":"6e77a79a-6073-4141-8dd8-cc4d9d61de69","acronym":"","url":"https://clinicaltrials.gov/study/NCT07101900","created_at":"2025-08-09T14:52:51.285Z","updated_at":"2025-08-09T14:52:51.285Z","phase":"Phase 2","brief_title":"68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses","source_id_and_acronym":"NCT07101900","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 100","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-08-08"},{"id":"69f52b30-5163-4f46-8cbc-94e44a11b34d","acronym":"NYCRCCL","url":"https://clinicaltrials.gov/study/NCT06949215","created_at":"2025-09-07T01:25:44.584Z","updated_at":"2025-09-07T01:25:44.584Z","phase":"Phase 2","brief_title":"68Ga-NYM096 PET/ CT for the Detection of ccRCC in Presurgical Patients With Complex Cystic Renal Leision","source_id_and_acronym":"NCT06949215 - NYCRCCL","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-04-29"},{"id":"e994ddd8-c8c2-48db-9917-ca57ceffe9a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04995185","created_at":"2021-08-06T12:53:11.830Z","updated_at":"2024-07-02T16:35:03.536Z","phase":"","brief_title":"18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study","source_id_and_acronym":"NCT04995185","lead_sponsor":"National Cancer Centre, Singapore","biomarkers":" HIF1A • CA9","pipe":" | ","alterations":" HIF1A expression • VEGFA expression • CA9 expression","tags":["HIF1A • CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HIF1A expression • VEGFA expression • CA9 expression"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 06/20/2017","start_date":" 06/20/2017","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2024-05-15"},{"id":"561428b5-f2b3-4959-8d03-ea3cd30a25f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00892866","created_at":"2021-01-18T03:25:21.231Z","updated_at":"2024-07-02T16:35:06.201Z","phase":"","brief_title":"CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells","source_id_and_acronym":"NCT00892866","lead_sponsor":"GOG Foundation","biomarkers":" CA9 • MCM2","pipe":" | ","alterations":" CA9 expression","tags":["CA9 • MCM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9 expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 877","initiation":"Initiation: 04/13/2009","start_date":" 04/13/2009","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-05-03"},{"id":"694735df-ac85-49ba-93fc-bc6caa6ca10b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05868174","created_at":"2023-05-22T16:05:29.186Z","updated_at":"2025-02-25T16:18:49.188Z","phase":"Phase 1","brief_title":"Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors","source_id_and_acronym":"NCT05868174","lead_sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • 177Lu-DOTA-girentuximab (TLX250) • Rencarex (girentuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/23/2023","start_date":" 05/23/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-01"},{"id":"d77b6c89-cb48-4369-b0dc-51bba650225a","acronym":"LACC-MET","url":"https://clinicaltrials.gov/study/NCT06353061","created_at":"2024-04-08T18:25:19.565Z","updated_at":"2024-07-02T16:35:11.016Z","phase":"Phase 2","brief_title":"Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer","source_id_and_acronym":"NCT06353061 - LACC-MET","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 04/15/2024","start_date":" 04/15/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-08"},{"id":"5a1f1c7f-5042-4321-ba07-3587d0d263c2","acronym":"PEP-C","url":"https://clinicaltrials.gov/study/NCT04053855","created_at":"2021-01-18T19:52:35.235Z","updated_at":"2024-07-02T16:35:31.587Z","phase":"","brief_title":"Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma","source_id_and_acronym":"NCT04053855 - PEP-C","lead_sponsor":"Centre Hospitalier Universitaire de Saint Etienne","biomarkers":" CA9 • CD9 • CD81","pipe":"","alterations":" ","tags":["CA9 • CD9 • CD81"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/29/2020","start_date":" 01/29/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2023-10-26"},{"id":"cfbc1c8e-cbb3-471a-bb95-0c96f732d2ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT05879510","created_at":"2023-05-30T14:05:09.190Z","updated_at":"2024-07-02T16:35:43.050Z","phase":"Phase 2","brief_title":"68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses","source_id_and_acronym":"NCT05879510","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-07-13"},{"id":"8f8e6e57-ee1a-46b1-bbd2-a9cebc9ec716","acronym":"SELECT","url":"https://clinicaltrials.gov/study/NCT00554515","created_at":"2021-01-18T02:01:16.594Z","updated_at":"2024-07-02T16:35:45.564Z","phase":"Phase 2","brief_title":"The High-Dose Aldesleukin (IL-2) \"Select\" Trial for Patients With Metastatic Renal Cell Carcinoma","source_id_and_acronym":"NCT00554515 - SELECT","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" PD-L1 • CD276 • CA9","pipe":"","alterations":" ","tags":["PD-L1 • CD276 • CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin)"],"overall_status":"Completed","enrollment":" Enrollment 123","initiation":"Initiation: 11/01/2006","start_date":" 11/01/2006","primary_txt":" Primary completion: 10/31/2013","primary_completion_date":" 10/31/2013","study_txt":" Completion: 10/31/2013","study_completion_date":" 10/31/2013","last_update_posted":"2023-06-15"},{"id":"943dda56-e7f0-4946-96ee-d51318451cb0","acronym":"CAMP1","url":"https://clinicaltrials.gov/study/NCT05698238","created_at":"2023-01-26T16:02:19.184Z","updated_at":"2024-07-02T16:35:53.273Z","phase":"Phase 1","brief_title":"Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT05698238 - CAMP1","lead_sponsor":"Mabpro, a.s.","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9hu-1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-03-15"},{"id":"9616c2d2-5400-434d-9a4a-0bdbdb7663da","acronym":"PERTINENCE","url":"https://clinicaltrials.gov/study/NCT04897763","created_at":"2021-05-24T16:53:38.292Z","updated_at":"2024-07-02T16:35:55.050Z","phase":"Phase 1","brief_title":"Assessment of safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC)","source_id_and_acronym":"NCT04897763 - PERTINENCE","lead_sponsor":"Institut Cancerologie de l'Ouest","biomarkers":" CA9","pipe":" | ","alterations":" CA9 expression","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rencarex (girentuximab)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 08/24/2022","primary_completion_date":" 08/24/2022","study_txt":" Completion: 09/26/2022","study_completion_date":" 09/26/2022","last_update_posted":"2023-02-21"},{"id":"9f6aadae-4c02-4885-9474-ee02d40d74f7","acronym":"OPALESCENCE","url":"https://clinicaltrials.gov/study/NCT04758780","created_at":"2021-02-17T14:01:01.787Z","updated_at":"2024-07-02T16:35:55.082Z","phase":"Phase 2","brief_title":"Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT04758780 - OPALESCENCE","lead_sponsor":"Institut Cancerologie de l'Ouest","biomarkers":" HER-2 • ER • PGR • CA9","pipe":" | ","alterations":" CA9 expression","tags":["HER-2 • ER • PGR • CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rencarex (girentuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 09/21/2021","start_date":" 09/21/2021","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-02-21"},{"id":"1bdfa3c5-3480-4494-ac29-f5c50d54ac49","acronym":"","url":"https://clinicaltrials.gov/study/NCT05214885","created_at":"2022-02-05T18:27:39.891Z","updated_at":"2024-07-02T16:36:15.793Z","phase":"","brief_title":"Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma","source_id_and_acronym":"NCT05214885","lead_sponsor":"Qianfoshan Hospital","biomarkers":" CA9 • NDUFA4L2 • EGLN3","pipe":" | ","alterations":" CA9 expression","tags":["CA9 • NDUFA4L2 • EGLN3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 02/11/2022","start_date":" 02/11/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2022-03-09"},{"id":"4ad14ef8-b4e9-4380-9939-f8359daf8bbc","acronym":"HEAD-MET","url":"https://clinicaltrials.gov/study/NCT03510390","created_at":"2021-01-18T17:16:43.390Z","updated_at":"2024-07-02T16:36:20.573Z","phase":"","brief_title":"Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation","source_id_and_acronym":"NCT03510390 - HEAD-MET","lead_sponsor":"University Hospital Inselspital, Berne","biomarkers":" TP53 • VEGFA • HIF1A • HMOX1 • NFKB1 • CA9 • CASP3 • MMP9 • SERPINE1 • PER1 • APEX1 • EGLN1 • EGR1 • HNF1A • PLAU • NCOA1","pipe":"","alterations":" ","tags":["TP53 • VEGFA • HIF1A • HMOX1 • NFKB1 • CA9 • CASP3 • MMP9 • SERPINE1 • PER1 • APEX1 • EGLN1 • EGR1 • HNF1A • PLAU • NCOA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 06/13/2018","start_date":" 06/13/2018","primary_txt":" Primary completion: 09/15/2021","primary_completion_date":" 09/15/2021","study_txt":" Completion: 11/15/2021","study_completion_date":" 11/15/2021","last_update_posted":"2021-11-18"},{"id":"59147de9-a288-4465-b490-08d521c36c94","acronym":"ZIRDAC-JP","url":"https://clinicaltrials.gov/study/NCT04496089","created_at":"2021-01-18T21:35:36.413Z","updated_at":"2024-07-02T16:36:25.928Z","phase":"Phase 1","brief_title":"Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC","source_id_and_acronym":"NCT04496089 - ZIRDAC-JP","lead_sponsor":"Telix International Pty Ltd","biomarkers":" CA9","pipe":" | ","alterations":" CA9 expression","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rencarex (girentuximab)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 08/01/2020","start_date":" 08/01/2020","primary_txt":" Primary completion: 10/27/2020","primary_completion_date":" 10/27/2020","study_txt":" Completion: 04/06/2021","study_completion_date":" 04/06/2021","last_update_posted":"2021-08-24"},{"id":"9ccb79fc-ad6a-4a61-8273-9ffc47d90e09","acronym":"Zip Up","url":"https://clinicaltrials.gov/study/NCT05018442","created_at":"2021-08-24T11:52:55.186Z","updated_at":"2024-07-02T16:36:25.944Z","phase":"Phase 1/2","brief_title":"89Zr-girentuximab PET in Urothelial Cancer Patients","source_id_and_acronym":"NCT05018442 - Zip Up","lead_sponsor":"Telix International Pty Ltd","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rencarex (girentuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/03/2021","start_date":" 08/03/2021","primary_txt":" Primary completion: 02/28/2022","primary_completion_date":" 02/28/2022","study_txt":" Completion: 05/31/2022","study_completion_date":" 05/31/2022","last_update_posted":"2021-08-24"},{"id":"9b7e6782-691d-4512-99cc-b7cc0fd6267c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01826877","created_at":"2021-01-18T08:07:04.786Z","updated_at":"2024-07-02T16:36:26.922Z","phase":"Phase 1","brief_title":"Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer","source_id_and_acronym":"NCT01826877","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DC-AdGMCAIX"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 01/14/2013","start_date":" 01/14/2013","primary_txt":" Primary completion: 07/03/2018","primary_completion_date":" 07/03/2018","study_txt":" Completion: 05/27/2021","study_completion_date":" 05/27/2021","last_update_posted":"2021-08-04"},{"id":"496e0445-dcdb-48da-893b-bdfb3734dff2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04969354","created_at":"2021-07-20T14:52:39.853Z","updated_at":"2024-07-02T16:36:27.687Z","phase":"Phase 1","brief_title":"Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT04969354","lead_sponsor":"The Affiliated Hospital of Xuzhou Medical University","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2021-07-20"},{"id":"66bc3f88-573e-483d-a074-c5b181266d2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01297244","created_at":"2021-01-18T05:16:20.218Z","updated_at":"2024-07-02T16:36:39.586Z","phase":"Phase 2","brief_title":"A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT01297244","lead_sponsor":"AVEO Pharmaceuticals, Inc.","biomarkers":" HGF • IL2 • VEGFD • CA9 • VEGFB • VEGFC • CD68","pipe":"","alterations":" ","tags":["HGF • IL2 • VEGFD • CA9 • VEGFB • VEGFC • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fotivda (tivozanib)"],"overall_status":"Completed","enrollment":" Enrollment 105","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 10/01/2012","study_completion_date":" 10/01/2012","last_update_posted":"2020-10-27"},{"id":"bcf15195-c582-4c5b-a785-0925f76d7048","acronym":"MISOBOLD","url":"https://clinicaltrials.gov/study/NCT03293602","created_at":"2021-01-18T16:16:15.727Z","updated_at":"2024-07-02T16:36:53.124Z","phase":"","brief_title":"MISOBOLD - Prostate Cancer Hypoxia Using BOLD MRI and 18F-MISO PET Imaging","source_id_and_acronym":"NCT03293602 - MISOBOLD","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" HIF1A • CA9","pipe":"","alterations":" ","tags":["HIF1A • CA9"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2019-11-27"},{"id":"ba768302-dd29-4250-bc83-4b97e5814f45","acronym":"","url":"https://clinicaltrials.gov/study/NCT00087022","created_at":"2021-01-18T00:15:20.219Z","updated_at":"2024-07-02T16:37:05.048Z","phase":"Phase 3","brief_title":"Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer","source_id_and_acronym":"NCT00087022","lead_sponsor":"Heidelberg Pharma AG","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rencarex (girentuximab)"],"overall_status":"Completed","enrollment":" Enrollment 864","initiation":"Initiation: 07/01/2004","start_date":" 07/01/2004","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 10/01/2012","study_completion_date":" 10/01/2012","last_update_posted":"2018-11-27"},{"id":"c679c891-db2e-48af-a57b-9b8c26706382","acronym":"","url":"https://clinicaltrials.gov/study/NCT00381797","created_at":"2021-01-18T01:19:39.832Z","updated_at":"2024-07-02T16:37:16.033Z","phase":"Phase 2","brief_title":"Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma","source_id_and_acronym":"NCT00381797","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KDR • EPAS1 • CA9","pipe":" | ","alterations":" VEGFA overexpression • VEGFA expression • CA9 expression","tags":["KDR • EPAS1 • CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VEGFA overexpression • VEGFA expression • CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • irinotecan"],"overall_status":"Completed","enrollment":" Enrollment 97","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2017-11-28"},{"id":"cb2e387c-ff93-4e81-b7e1-878920bde6ce","acronym":"RHYTHM-I","url":"https://clinicaltrials.gov/study/NCT02157246","created_at":"2021-01-18T10:02:00.516Z","updated_at":"2024-07-02T16:37:24.482Z","phase":"","brief_title":"RHYTHM-I: Investigating Hypoxia in Rectal Tumours","source_id_and_acronym":"NCT02157246 - RHYTHM-I","lead_sponsor":"University of Oxford","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 10/01/2013","start_date":" 10/01/2013","primary_txt":" Primary completion: 11/01/2016","primary_completion_date":" 11/01/2016","study_txt":" Completion: 11/01/2016","study_completion_date":" 11/01/2016","last_update_posted":"2017-03-13"},{"id":"af101178-d0fc-4324-b949-69dd12bb1043","acronym":"","url":"https://clinicaltrials.gov/study/NCT02787915","created_at":"2021-01-18T13:40:37.028Z","updated_at":"2024-07-02T16:37:31.545Z","phase":"Phase 1/2","brief_title":"DC1s-CTL Cellular Therapy for Renal Cell Carcinoma","source_id_and_acronym":"NCT02787915","lead_sponsor":"Xuzhou Medical University","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 08/01/2019","primary_completion_date":" 08/01/2019","study_txt":" Completion: 08/01/2019","study_completion_date":" 08/01/2019","last_update_posted":"2016-06-02"}]